The FDA’s electronic data mining is an adequate method for finding unknown mifepristone risks

Law and political conflict over abortion access, contraception, fertility treatment and the medical care surrounding pregnancy in the United States. Returned largely to the states by the Supreme Court's 2022 Dobbs ruling, and fought since through ballot measures, legislatures and courts.

Food and Drug Administration officials said in a court filing disclosed October 7, 2026, that their safety review of mifepristone would not be completed until March. The agency will continue evaluating the abortion drug, extending a review central to its distribution rules.